EP3752011A1 - Flüssigkeitsdampfbasis und extraktionsverfahren - Google Patents
Flüssigkeitsdampfbasis und extraktionsverfahrenInfo
- Publication number
- EP3752011A1 EP3752011A1 EP19751397.1A EP19751397A EP3752011A1 EP 3752011 A1 EP3752011 A1 EP 3752011A1 EP 19751397 A EP19751397 A EP 19751397A EP 3752011 A1 EP3752011 A1 EP 3752011A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- weight
- base
- mixture
- botanicals
- propanediol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
- A24B15/281—Treatment of tobacco products or tobacco substitutes by chemical substances the action of the chemical substances being delayed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/10—Chemical features of tobacco products or tobacco substitutes
- A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
- A24B15/167—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
- A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
- A24B15/302—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances by natural substances obtained from animals or plants
- A24B15/303—Plant extracts other than tobacco
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
Definitions
- the present invention relates generally to compositions of matter, methods for extraction and production and the products resulting therefrom, all associated with vaping solutions for inhalation and bases for generating the vaping solutions.
- vaping is the process of atomizing a solution and inhaling the resulting vapors.
- a solution may include a liquid product (e.g., base), that may include certain additives, which serves as a carrier for a variety of active ingredients which are added to the base to form a vaping solution.
- base may carry the active ingredients for delivery to a user's lungs.
- Conventional vaping solutions thus comprise a base (including additives) and active ingredients.
- the base includes the liquids that form the bulk of the solution.
- the additives may include flavorings and other ingredients that enhance the vaping experience.
- the active ingredients are the ingredients that provide the desired vaping effect such as psychoactive effects, delivery of medicine and delivery of healthful agents or recreational products, among others.
- vaping There are any number of uses and motivations for vaping. For example, smokers frequently turn to vaping as an alternative to cigarettes.
- nicotine may be one of several active ingredients added to a base and delivered into the bloodstream through inhalation of the vaping solution into the lungs.
- Many other agents may be delivered in this manner and other components, such as flavorings, may be added.
- e-cigarette electronic cigarette
- Many e-cigarettes include a heating element which converts the solution into a vapor.
- some e-cigarettes utilize a piezoelectric diaphragm for the atomization.
- the design of an e-cigarette is generally intended to maintain the solution and vapors at a temperature below ignition. In this regard, it is often believed that vaping is healthier than smoking cigarettes at least because there are no burned substances entering the lungs.
- glycol is a consistent and stable carrier for additives and active ingredients that allows specific dosing when subjected to extreme heat.
- PG propylene glycol
- PEG polyethylene glycol
- glycol is considered by many to be an undesirable product for ingestion because it is a synthetic, rather than natural, product and because of connotations associated with its common industrial applications (e.g., production of polyester resins and polyurethanes, aircraft deicing).
- connotations associated with its common industrial applications e.g., production of polyester resins and polyurethanes, aircraft deicing.
- certain glycols to be carcinogenic and many users of e-cigarettes report undesirable side effects from glycol bases such as throat irritation.
- the present invention includes subject matter (e.g., methods, compositions, products-by- processes etc.) related to a liquid base useful for vaping that comprises entirely or substantially entirely naturally occurring substances.
- a liquid base useful for vaping that comprises entirely or substantially entirely naturally occurring substances.
- naturally occurring substances may be replicated in the laboratory for improved process control, but substances that do not occur in nature are avoided to the maximum extent possible.
- the products can be produced using renewable plant- based materials free from preservatives or synthetic chemicals, and can be sourced so that the ingredients are traceable from farm to final product.
- Such a base may be healthier for a user's respiratory system and may act to detoxify and even heal the lungs while providing a carrier or delivery system for additional ingredients including active ingredients (e.g., extracts, compositions, and flavorings).
- active ingredients e.g., extracts, compositions, and flavorings.
- the intended uses of embodiments of the invention may cover, inter alia , nicotine e- cigarettes, tobacco, THC vaping, bronchial inhalers, medications, vitamins, and dietary supplements. While much of the description below makes use of specific examples in discussing various aspects of the invention, such examples are intended merely for illustrative purposes and the invention is not limited to any specific operational characteristics disclosed herein.
- bases and vapes are described below that include two primary components that form the bulk of the bases and certain “additives” that impart certain desired qualities to the bases. Such bases are sometimes referred to as carriers or thinners according to their use, and the“bases” of the present invention are intended to encompass such products regardless of the label.
- A“vape” is produced by adding“additional ingredients” to the base.
- the additional ingredients may include“active ingredients” to produce the desired vaping effect and other ingredients such as flavorings or the like.
- a particular component may be an additive or an additional ingredient depending on how it is used. Manufacturers may consider interactions or other cumulative effects associated with the combinations of additives and additional ingredients in a vape to avoid harmful effects and to optimize dosing and desired effects.
- a composition for use in producing a vaping product. That is, the composition may be added to other components to yield a base or a vape.
- the composition includes at least two botanicals from the group consisting of lobelia, coltsfoot, eucalyptus, lungwort, oregano, and algae. Each of these botanicals has been found to provide benefits related to improved throat feel and healing of the respiratory tract when inhaled in a vaping product. In particular, as the botanicals each provide unique and complementary benefits, combinations of two or more of these botanicals are believed to be particularly beneficial.
- different ones of these botanical s may be combined so as to yield effects associated with an expectorant, an antitussive, an anti-inflammatory, an astringent, a tonic, an antioxidant, a humectant, or any desired combination and weighting of the desired effects.
- a combination of all of the noted botanicals is believed to be particularly beneficial, but it is anticipated that excellent products may be produced while eliminating one of the botanicals (i.e., using the other five) as may be desired to avoid any potential interaction, effect or supply difficulty.
- the noted botanicals may be added to various bases or combinations of base components to yield an improved base. Particular combinations of base components are described below, but others may be used in accordance with the present invention.
- the botanicals may provide benefits even when used in connection with conventional bases noted above.
- a medium chain triglyceride (MCT) or other base may be used in place of the bases described below or in place of a component thereof, may be used with modified formulations of the botanicals to form a base, or may be used as a base or base components with specific vape formulations described below or modified versions thereof (e.g., the account for interactions specific to MCT).
- MCT formulations may be specifically used in low temperature vaping implementations (e.g., at temperatures not exceeding 200°C).
- a base for use in manufacturing a vape.
- the base includes propanediol, a glycerin such as vegetal glycerin (VGt) and a blend of two or more botanical additives.
- the propanediol and VGt may be lab produced for improved consistency.
- the botanicals may be, for example, selected from the group lobelia, coltsfoot, eucalyptus, lungwort, oregano, and algae juice as discussed above. In one implementation, all of the noted botanical additives may be used. It is been found that the botanical additives provide a base that has a smoother impression and reduces or eliminates throat bum.
- a vape in accordance with a still further aspect of the present invention, includes a base and one or more active ingredients for producing a desired physiological effect.
- the base may comprise ingredients as described above including the botanical additives.
- the active ingredients may include an ingredient selected from cannabidiol, tetrahydrocannabinol, nicotine, guarana, caffeine, a dietary supplement, a vitamin, and medication. Additional ingredients such as flavorings may be included.
- a method for use in producing a vaping product such as a base and/or a vape.
- the method includes blending propanediol and VGt to form a mixture, blending a plurality of additives into the mixture, and mixing the additives into the mixture to form a base.
- the mixture may be maintained at a temperature of, for example, between about 90°F - l20°F during this process.
- the base may then be used to form a vape.
- an active ingredient may be blended with the base to form the vape.
- the active ingredient may be selected from the group cannabidiol, tetrahydrocannabinol, nicotine, guarana, caffeine, a dietary supplement, a vitamin, and medication.
- the invention further includes products produced by the noted processes.
- a vape comprises a base and active components including at least two ingredients selected from the group holy basil, saffron, ashwagandaha, licorice, gotu kola, and Saint John’s wort. These ingredients, in various combinations, have been found to provide enhanced energy when inhaled in a vape. Certain formulations include five of these ingredients (an energy vape omits Saint John’s wort and a sustained energy vape excludes gotu kola).
- FIG. 1 is a flowchart illustrating a process for producing a vaping product in accordance with the present invention. Detailed Description
- the present invention is based in part on the desire to create an improved product that would not flash or ignite at high temperatures found in atomizers of some vape devices.
- an initial objective was to find natural plants, herbs and/or botanicals that could be combined with a vegetal or vegetable glycerin (VGt) to form a substitute for glycols.
- the botanicals oxygenate the smoking process to reduce throat irritation while remaining non-toxic even at the flash points of the various ingredients.
- the invention also provides base liquids and additives that are not prone to ignite at temperatures found in atomizers as ignition may lead to free radicals, oxidation, tar, and lacquering, thereby leaving residue and harmful substances in the lungs.
- a replacement for propylene glycol has been developed that is made from natural ingredients that may effectively deliver the desired additive(s).
- this liquid base is naturally derived from traditional corn-based propanediol which is made by fermenting com.
- propanediol is thus made from natural ingredients, it may be laboratory produced for consistency and optimized properties.
- Laboratory-produced propanediol has been found to provide favorable boiling points, melting points, and densities compared to other propanediols.
- the laboratory-produced propanediol (“LPP”) mixes well with a laboratory- produced vegetable glycerin resulting in reduced toxicity liquid base that will stay in stable composition with the additives (e.g., botanical elements).
- the additives e.g., botanical elements.
- vegetal glycerin blends which may be suitable for the present invention.
- a vegetal glycerin derived from steam distillation of com seeds, leaves, or husks is blended with a triglyceride mixture distilled from coconut, soy, and bamboo to yield VGt.
- the VGt is thus made from natural ingredients, it may be laboratory produced for consistency and optimized properties, thus yielding a laboratory-produced vegetable glycerin (“LPVGt”).
- Suitable propanediol and glycerin products that are not laboratory produced are available in the marketplace. These products include 1.3 -Propanediol (e.g., Du Pont® Zemea®) and Vegetable Glycerin USP 99%. Exemplary bases may include about 45 - 55% LPP and about 45 - 50% LPVGt as described below.
- Volatile oils may be extracted from herbal and botanical substances (“botanicals”) for use as additives.
- Various processes may be utilized for extraction including, but not limited to, liquid extraction, steam distillation, centrifugal processing, extrusion, and/or oxygen micronization.
- the order of processing steps and enhancements to be performed on certain extractions may be altered to affect characteristics of the base.
- An extraction process may be selected for each particular botanical with the objective of yielding the most pure and desirable result for that particular botanical.
- Additives used in conjunction with a base may include, inter alia , lobelia, coltsfoot, eucalyptus, lungwort, oregano, and algae juice. These botanicals can be tracked from their origins to production to ensure quality and purity.
- the above-the-ground parts of the lobelia plant (Lobelia inflata) are used, among other things, because they contain chemicals that thin mucous to aid expectoration.
- the leaves of the coltsfoot plant (Tussilago farfara) are used at least to make medicines that help with lung problems such as bronchitis by reducing swelling and inflammation.
- the dried leaves and oil of the eucalyptus tree (Eucalyptus globulus) are known to loosen coughs and to treat respiratory tract infections and reduce the swelling of the mucous membranes of the respiratory tract.
- the aerial parts of the lungwort plant (Pulmonaria officinalis) are known to treat breathing conditions and are often used in cough medicines.
- the leaves of the oregano plant (Origanum vulgare) are known to reduce coughs and spasms, and possess antioxidant properties. Algae, in its many forms, is incorporated as a juice because of its antioxidant and humectant properties.
- the combination of the listed botanicals creates a comprehensive, 100% natural, vaping base to reduce throat bum by simultaneously soothing and healing the respiratory tract.
- the botanical matrix provides beneficial moisture to oral tissues, reduces inflammation, and delivers tonic properties and antioxidants to allow a more enjoyable vaping experience. It will be appreciated that the effects noted above for the various additives are provided by way of example and the additives may have additional effects, both known and unknown. These additives and certain of their effects are summarized in the table below.
- a solution may comprise 1-10% lobelia (more preferably, between about 1-3%), 0.5-5% coltsfoot (more preferably, between about 0.5-2%), 0.5-5% eucalyptus (more preferably, between about 0.5-2%), 0.25-2.5% lungwort (more preferably, between about 0.25-1%), 0.25-2.5% oregano (more preferably, between about 0.25-1%), and 0.1-2.5% algae juice (more preferably, between about 0.1-0.5%).
- a solution may comprise about 2% lobelia, 1% coltsfoot, 1% eucalyptus, 0.5% lungwort, 0.5% oregano, and 0.25% algae juice, by weight or by volume.
- lobelia may comprise a lobeline extrusion processed liquid extraction and a centrifuge and micronization with oxygen; coltsfoot may be extracted with steam distillation; eucalyptus may be extracted from cineole with steam distillation; lungwort may be extruded to extract volatile juice and oil or liquid extraction; oregano may be extruded or extracted by liquid extraction and homogenized, and algae juice may be micronized with oxygen, e.g., to act as a humectant and keep lungs moist.
- some ingredients may be encapsulated using standard laboratory processes. Encapsulation may discourage tampering with the formulation or reverse engineering. Trace elements and minerals may also be employed in the additives to make them clinically relevant to batch compounding.
- the present invention includes the additives and the way they are compounded. All of the ingredients (e.g., liquid base and additives) may be cool-compounded into solution by screwing at a temperature below 180 °F, more preferably at a temperature between about 145 - 160 °F, for example, 152 °F. It is believed that temperatures above 180 °F may undesirably cook the ingredients.
- All of the ingredients e.g., liquid base and additives
- All of the ingredients may be cool-compounded into solution by screwing at a temperature below 180 °F, more preferably at a temperature between about 145 - 160 °F, for example, 152 °F. It is believed that temperatures above 180 °F may undesirably cook the ingredients.
- Any appropriate production process may be utilized. The following is a description of one implementation of a therapeutic formulation produced by a production process (100), and is provided for exemplary purposes, with reference to the flowchart of Fig. 1 :
- the illustrated process is initiated by creating a base by mixing (102) 48.7% propanediol (e.g., LPP) and 46% vegetal glycerin (e.g., LPVGt) in a vat with a scraper, and fermenting (104) at 106 °F for approximately three hours or until the mixture loses it milky white appearance (e.g., may become translucent).
- This mixture induces a fermentation process.
- the laboratory fermentation process includes the use of yeast in a first phase of the process, and then a bacterial culture in a second phase.
- solids are filtered out of the liquid by using a 50-60 micron filtration screen. Accordingly, it may be desirable to monitor and control (106) yeast and bacterial counts to be congruent with lab standards for traditional fermentation.
- the resulting mixture is then homogenized.
- the additives e.g., botanical and herbal ingredients such as lobelia, coltsfoot, eucalyptus, lungwort, oregano and algae juice
- botanical and herbal ingredients such as lobelia, coltsfoot, eucalyptus, lungwort, oregano and algae juice
- This blend of ingredients should be pre-measured, compounded, sealed and allowed to set (110) for approximately 12 hours at room temperature.
- the entire matrix is then run through homogenization (which helps bind oxygen) for 10 minutes.
- the additives are mixed (112) into the base.
- the finished matrix may be slowly
- Light extrusion screwing (114) may be utilized for 5-6 hours or until no separation occurs.
- the matrix is then homogenized (116) for about 10-30 minutes or until fully oxygenized and the solution is fully integrated with no sign of separation. [0038] The resulting product can then be tested (118) for appropriate safety and efficacy.
- the product is promptly poured into drums or any appropriate packaging (120) that can be medically sealed.
- a specific example of a base according to the present invention includes the following ingredients:
- ingredients may be processed as described above to yield a base in accordance with the present invention.
- the resulting solution is believed to be a safe and effective carrier for additional ingredients including active ingredients which may be added alternatively or additionally to the described additives to yield a vape.
- active ingredients which may be added alternatively or additionally to the described additives to yield a vape.
- active ingredients for example, CBD, THC, marijuana, tobacco, nicotine, guarana/caffeine, dietary supplements, vitamins, and medications or combinations thereof may be employed as active ingredients depending on the desired effect.
- the described formulation may be modulated to generate more or less steam vapor by altering the ratio of LPVGt to LPP. Furthermore, embodiments of the described composition of matter may be flavored.
- the base may be, in each case, formulated and processed as described above. However, it will be appreciated that manufacturers may perform research and testing concerning interactions or other combined effects as between the base additives and the additional ingredients used to generate the vape. Accordingly, the bases used for forming the vapes below may include a full set of additives as described above, or at least a subset of such additives, but it is possible that certain vapes may eliminate all of the additives.
- a herbal mix is added to the base to produce an“energy vape.”
- the herbal mix includes:
- Gobi kola (Brahmi) leaf - Centella asiatica or,
- both a regular energy vape and a sustained energy vape are provided.
- the botanic matrices of these energy vapes are further described in the tables below:
- Each ingredient in this formulation is used in substantially equal amounts to provide the total formula, and it is prepared in a manner similar to therapeutic botanical formulation described above, with liquid extraction, and combined as a concentrate that would be poured into the LPP-LPVGt base on top of the therapeutic botanical matrix discussed above. Any additional ingredients such as THC, CBD, nicotine or a flavoring would be added and“lightly mixed” during the original 5-6 hours, and again homogenized until full oxygenized. Again, potential interactions and other combinative effects may be considered in relation to the base additives and vape ingredients, or any other combination of components. In particular, some researchers have noted potential concerns or interactions related to gotu kola and Saint John’s wort. Thus, it is anticipated that these may be eliminated from the formulations noted above or other ingredients may be added or substituted.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Toxicology (AREA)
- Agronomy & Crop Science (AREA)
- Pulmonology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862629453P | 2018-02-12 | 2018-02-12 | |
| US201862630487P | 2018-02-14 | 2018-02-14 | |
| PCT/US2019/017716 WO2019157526A1 (en) | 2018-02-12 | 2019-02-12 | Liquid vape base and extraction process |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EP3752011A1 true EP3752011A1 (de) | 2020-12-23 |
| EP3752011A4 EP3752011A4 (de) | 2022-01-19 |
| EP3752011B1 EP3752011B1 (de) | 2026-04-01 |
Family
ID=67540666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP19751397.1A Active EP3752011B1 (de) | 2018-02-12 | 2019-02-12 | Flüssigkeitsdampfbasis und extraktionsverfahren |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11957786B2 (de) |
| EP (1) | EP3752011B1 (de) |
| AU (1) | AU2019218399B2 (de) |
| CA (1) | CA3091014A1 (de) |
| DK (1) | DK3752011T3 (de) |
| ES (1) | ES3075673T3 (de) |
| FI (1) | FI3752011T3 (de) |
| PT (1) | PT3752011T (de) |
| WO (1) | WO2019157526A1 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112870240A (zh) * | 2021-02-05 | 2021-06-01 | 山西大学 | 款冬花在制备预防香烟烟雾暴露致肺损伤产品中的应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014125340A1 (en) | 2013-02-15 | 2014-08-21 | Pharmaday S.R.L. | Smoke liquid for atomizers and/or vaporizers |
| CN104585870A (zh) | 2015-01-20 | 2015-05-06 | 川渝中烟工业有限责任公司 | 一种具有止咳润肺功能的电子烟烟液 |
| US20160174603A1 (en) | 2014-12-23 | 2016-06-23 | Sahan Abayarathna | Electronic Vapor Liquid Composition and Method of Use |
| US20160262443A1 (en) | 2014-03-11 | 2016-09-15 | Laboratoires Ceres | Use of a composition containing 1,3-propanediol as e-liquid |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0104388D0 (sv) * | 2001-12-27 | 2001-12-27 | Pharmacia Ab | New formulation and use and manufacture thereof |
| CN101919584B (zh) | 2010-08-16 | 2012-08-29 | 深圳市如烟生物科技有限公司 | 纤体功能型电子烟烟液 |
| PL2925395T3 (pl) * | 2012-11-28 | 2019-08-30 | Fontem Holdings 1 B.V. | Urządzenie wytwarzające aerozol kondensacyjny z ciekłej formulacji |
| ITMI20131138A1 (it) * | 2013-07-05 | 2015-01-06 | Paolo Marzorati | Composizioni vaporizzabili per sigarette elettroniche |
-
2019
- 2019-02-12 EP EP19751397.1A patent/EP3752011B1/de active Active
- 2019-02-12 WO PCT/US2019/017716 patent/WO2019157526A1/en not_active Ceased
- 2019-02-12 ES ES19751397T patent/ES3075673T3/es active Active
- 2019-02-12 CA CA3091014A patent/CA3091014A1/en active Pending
- 2019-02-12 DK DK19751397.1T patent/DK3752011T3/da active
- 2019-02-12 PT PT197513971T patent/PT3752011T/pt unknown
- 2019-02-12 US US16/274,081 patent/US11957786B2/en active Active
- 2019-02-12 FI FIEP19751397.1T patent/FI3752011T3/fi active
- 2019-02-12 AU AU2019218399A patent/AU2019218399B2/en active Active
-
2024
- 2024-04-15 US US18/635,979 patent/US20240398703A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014125340A1 (en) | 2013-02-15 | 2014-08-21 | Pharmaday S.R.L. | Smoke liquid for atomizers and/or vaporizers |
| US20160262443A1 (en) | 2014-03-11 | 2016-09-15 | Laboratoires Ceres | Use of a composition containing 1,3-propanediol as e-liquid |
| US20160174603A1 (en) | 2014-12-23 | 2016-06-23 | Sahan Abayarathna | Electronic Vapor Liquid Composition and Method of Use |
| CN104585870A (zh) | 2015-01-20 | 2015-05-06 | 川渝中烟工业有限责任公司 | 一种具有止咳润肺功能的电子烟烟液 |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO2019157526A1 |
Also Published As
| Publication number | Publication date |
|---|---|
| US11957786B2 (en) | 2024-04-16 |
| US20190247297A1 (en) | 2019-08-15 |
| EP3752011A4 (de) | 2022-01-19 |
| FI3752011T3 (fi) | 2026-06-30 |
| EP3752011B1 (de) | 2026-04-01 |
| AU2019218399A1 (en) | 2020-09-03 |
| US20240398703A1 (en) | 2024-12-05 |
| WO2019157526A1 (en) | 2019-08-15 |
| DK3752011T3 (da) | 2026-07-06 |
| PT3752011T (pt) | 2026-07-15 |
| CA3091014A1 (en) | 2019-08-15 |
| AU2019218399B2 (en) | 2024-11-07 |
| ES3075673T3 (en) | 2026-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2599826C2 (ru) | Биологически активная добавка | |
| JP7583809B2 (ja) | 活性成分の組合せを含む口腔用製品 | |
| CN104857073A (zh) | 紫草护肤中药组合物和紫草护肤膏及其制备方法 | |
| US20240398703A1 (en) | Liquid vape base and extraction process | |
| CN112107612A (zh) | 补气养血、美容养颜的中药组合物及其制备方法和应用 | |
| KR101512230B1 (ko) | 면역력 및 혈액순환 개선 기능을 갖는 관절염 치료 조성물과 그 제조방법 | |
| CN1836591A (zh) | 一种卷烟吸味改良剂及其制备和使用方法 | |
| KR100899278B1 (ko) | 화장료 조성물 | |
| CN113854623A (zh) | 一种不含尼古丁盐的本草低温雾化电子烟烟油 | |
| CN109758542B (zh) | 具有健胃作用的复合木香油脂肪乳制剂及制备方法与应用 | |
| EP1609466B1 (de) | Pharmazeutische Zusammensetzung, Verwendung dieser pharmazeutischen Zusammensetzung zur Herstellung eines Medikaments und/oder eines Nahrungsergänzungmittels zur Behandlung von Übergewicht und/oder Symptomen, die mit Übergewicht einhergehen, beim Menschen oder Säugetier, sowie Verfahren zur Herstellung dieser pharmazeutischen Zusammensetzung | |
| RU2375434C2 (ru) | Композиция ингредиентов для бальзама | |
| CN105878533A (zh) | 一种用于防治鸿雁养殖小鹅瘟病的中草药剂 | |
| WO2002024212A1 (en) | Cholesterol in blood-lowering composition and its complex, and method for preparing them | |
| WO2024078373A1 (zh) | 荷荷巴油在制备电子烟烟液中的应用 | |
| CN107006717A (zh) | 含有桑叶和蚕的鸡饲料 | |
| KR20190057727A (ko) | 기호성이 향상된 기관지 건강 약리 조성물 | |
| CN113786440A (zh) | 一种清咽利喉组合物及其应用 | |
| Muñoz et al. | Those responsible for the pharmacological actions of plants are the active secondary metabolites | |
| KR102470454B1 (ko) | 돌외잎 추출물 및 복합추출물을 포함하는 항비만용 건강기능식품 조성물, 및 이의 제조방법 | |
| KR102937420B1 (ko) | 가바(gaba), l-시스테인, 테아닌, 멜라토닌, 감초, 맥문동, 및 방풍을 포함하는 기능성 액상 조성물 | |
| DE60316681T2 (de) | Dampf-Fraktion von Glycine max (L.) merr. Samen und entsprechende Zusammensetzung | |
| KR102588877B1 (ko) | 국소지방분해용 주사제 조성물 및 이의 투여방법 | |
| Kataria et al. | The formulation and evaluation of herbal cough syrup | |
| KR20120116113A (ko) | 한약재와 선옥균을 이용한 연골 및 근육 강화용 조성물 및 그 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20200911 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20211221 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 47/46 20060101ALI20211215BHEP Ipc: A61K 36/61 20060101ALI20211215BHEP Ipc: A61K 47/10 20170101ALI20211215BHEP Ipc: A61K 36/53 20060101ALI20211215BHEP Ipc: A61K 36/34 20060101ALI20211215BHEP Ipc: A61K 36/30 20060101ALI20211215BHEP Ipc: A61K 36/28 20060101ALI20211215BHEP Ipc: A61K 36/02 20060101ALI20211215BHEP Ipc: A61K 31/465 20060101ALI20211215BHEP Ipc: A61K 31/353 20060101ALI20211215BHEP Ipc: A61K 31/05 20060101ALI20211215BHEP Ipc: A61K 9/00 20060101ALI20211215BHEP Ipc: A24B 15/167 20200101ALI20211215BHEP Ipc: A24F 47/00 20200101ALI20211215BHEP Ipc: A24B 15/30 20060101ALI20211215BHEP Ipc: A24B 15/16 20200101AFI20211215BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20240826 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A24B0015160000 Ipc: A24B0015280000 Ref country code: DE Ref legal event code: R079 Ref document number: 602019083105 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A24B0015160000 Ipc: A24B0015280000 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A24B 15/30 20060101ALI20250227BHEP Ipc: A24B 15/167 20200101ALI20250227BHEP Ipc: A61K 47/46 20060101ALI20250227BHEP Ipc: A61K 47/10 20170101ALI20250227BHEP Ipc: A61K 36/61 20060101ALI20250227BHEP Ipc: A61K 36/53 20060101ALI20250227BHEP Ipc: A61K 36/34 20060101ALI20250227BHEP Ipc: A61K 36/30 20060101ALI20250227BHEP Ipc: A61K 36/28 20060101ALI20250227BHEP Ipc: A61K 36/02 20060101ALI20250227BHEP Ipc: A61K 31/465 20060101ALI20250227BHEP Ipc: A61K 31/353 20060101ALI20250227BHEP Ipc: A61K 9/00 20060101ALI20250227BHEP Ipc: A61K 31/05 20060101ALI20250227BHEP Ipc: A24B 15/28 20060101AFI20250227BHEP |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTG | Intention to grant announced |
Effective date: 20251023 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: F10 Free format text: ST27 STATUS EVENT CODE: U-0-0-F10-F00 (AS PROVIDED BY THE NATIONAL OFFICE) Effective date: 20260401 Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602019083105 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: FI Ref legal event code: FGE |
|
| REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20260702 |
|
| REG | Reference to a national code |
Ref country code: EE Ref legal event code: FG4A Ref document number: E025906 Country of ref document: EE Effective date: 20260630 Ref country code: PT Ref legal event code: SC4A Ref document number: 3752011 Country of ref document: PT Date of ref document: 20260715 Kind code of ref document: T Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20260629 |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 3075673 Country of ref document: ES Kind code of ref document: T3 Effective date: 20260806 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: R17 Free format text: ST27 STATUS EVENT CODE: U-0-0-R10-R17 (AS PROVIDED BY THE NATIONAL OFFICE) Effective date: 20260807 |